@entity1358 associated with Xp11.2 translocation/ XXXX gene fusions: clinical experience and literature review.

@entity1 @entity66 @entity19409 @entity1358 @entity3 @entity715 @entity811
UNASSIGNED: ABSTRACT    Aim: To analyze the clinicopathological features of @entity1358 ( @entity1358 ) associated with Xp11.2 translocation/ @entity19409 gene fusions (Xp11.2 @entity1358 ) in our institution. MATERIALS _ METHODS: We screened 983 @entity1358 specimens. @entity19409 immunohistochemical staining and FISH assay confirmed 22 Xp11.2 RCCs out of 65 suspicious cases. Clinicopathological and treatment outcomes of 22 @entity1 were retrospectively analyzed. RESULTS: In total, 22 @entity1 included 13 females and nine males with a mean age of 27 years. Ten @entity1 showed gross @entity811 . Treatments included surgeries, immunotherapy and molecular-targeted therapy. Seven cases were at stage III/IV and four cases had tumor @entity715 or distant @entity3 . During a median follow-up of 34 months, 19 @entity1 were alive while three died of distant @entity3 . CONCLUSION: Xp11.2 @entity1358 is rare and FISH proved a useful diagnostic tool. Surgical resection achieved favorable outcome for @entity66 . Adult @entity1 at advanced stage had poorer outcomes even with postoperative adjuvant therapy.
